RSS Feeds
Use of β-Blockers in Patients with Reactive Airway Disease
- Shelley R. Salpeter, MD; and
- Thomas M. Ormiston, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
We agree that further study of the long-term effects of β-blockers in patients with reactive airway disease is needed. Our study demonstrated the safety of cardioselective β-blockers in patients with mild to moderate reactive airway disease who were followed for up to 4 weeks. We believe that this study paves the way for larger, long-term trials to be done. In the meta-analysis, patients who received a single dose or continued treatment with a cardioselective β-blocker had an increased FEV1 response to β-agonists compared with placebo. Furthermore, in the continued treatment trials, steroid use, asthma exacerbations, and hospitalizations did not increase.
We remind readers that the evidence for the benefit of β-blockers in conditions such as acute myocardial infarction, coronary artery disease, diabetes mellitus, and congestive heart failure, as well as in the perioperative period, is convincing and strong. Our analysis, which pooled results from 29 randomized, controlled trials, indicated that β-blocker use should not be withheld from patients with a history of reactive airway disease. We hope our study will encourage more widespread use of cardioselective β-blockers in patients who could benefit from them.
Shelley R. Salpeter, MD
Thomas M. Ormiston, MD
Santa Clara Valley Medical Center; San Jose, CA 95128
- Copyright ©2004 by the American College of Physicians
